Denali Therapeutics Inc. (DNLI) is a publicly traded company in the Unknown sector. Across all available filings, 24 corporate insiders have executed 704 transactions totaling $467.6M, demonstrating a bearish sentiment with -$457.7M in net insider flow. The most recent transaction on Sep 3, 2025 involved a transaction of 50,000 shares valued at $0.
No significant insider buying has been recorded for DNLI in the recent period.
No significant insider selling has been recorded for DNLI in the recent period.
Based on recent SEC filings, insider sentiment for DNLI is bearish with an Insider Alignment Score of 1/100 and a net flow of -$457.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Denali Therapeutics Inc. (DNLI) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 24 insiders are actively trading DNLI stock, having executed 704 transactions in the past 90 days. The most active insider is Douglas K. Bratton (Executive), who has made 7 transactions totaling $150.4M.
Get notified when executives and directors at DNLI file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Sep 3, 2025 | J. Watts Ryan | Executive | Gift | 50,000 | $N/A | $0 | |
| Aug 13, 2025 | Ho Carole | Executive | Sale | 806 | $14.64 | $11.8K | |
| Aug 12, 2025 | Ho Carole | Executive | Sale | 2,937 | $13.58 | $39.9K | |
| Aug 12, 2025 | O. Schuth Alexander | Executive | Sale | 2,937 | $13.58 | $39.9K | |
| Aug 5, 2025 | Ho Carole | Executive | Option Exercise | 44,655 | $0.68 | $30.4K | |
| Jul 9, 2025 | J. Watts Ryan | Executive | Option Exercise | 455,282 | $0.68 | $309.6K | |
| Jul 9, 2025 | J. Watts Ryan | Executive | Sale | 495,282 | $15.00 | $7.4M | Large |
| Jul 9, 2025 | J. Watts Ryan | Executive | Option Exercise | 40,000 | $5.28 | $211.2K | |
| Sep 13, 2024 | L. Sato Vicki | Executive | Sale | 1,020 | $30.00 | $30.6K | 10b5-1 |
| Sep 3, 2024 | L. Sato Vicki | Executive | Sale | 100 | $25.37 | $2.5K | 10b5-1 |
| Sep 3, 2024 | L. Sato Vicki | Executive | Sale | 2,980 | $24.99 | $74.5K | 10b5-1 |
| Aug 21, 2024 | Ho Carole | Executive | Sale | 5,907 | $24.96 | $147.4K | 10b5-1 |
| Aug 21, 2024 | Ho Carole | Executive | Sale | 14,098 | $24.41 | $344.1K | 10b5-1 |
| Aug 21, 2024 | O. Schuth Alexander | Executive | Sale | 2,547 | $24.78 | $63.1K | 10b5-1 |
| Aug 20, 2024 | Ho Carole | Executive | Sale | 2,453 | $23.79 | $58.4K | 10b5-1 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 495 | $462.7M | 97.6% |
Purchase(P) | 1 | $5.0M | 1.0% |
Exercise(M) | 83 | $4.3M | 0.9% |
Disposition(D) | 3 | $1.8M | 0.4% |
Payment(F) | 7 | $383.1K | 0.1% |
Award(A) | 50 | $102 | 0.0% |
Gift(G) | 11 | $0 | 0.0% |
Other(J) | 6 | $0 | 0.0% |
Conversion(C) | 48 | $0 | 0.0% |
Insider selling pressure at Denali Therapeutics Inc. has increased, with 24 insiders executing 704 transactions across all time. Total sales of $462.7M significantly outpace purchases of $5.0M, resulting in a net outflow of $457.7M. However, 50% of these transactions are pre-scheduled 10b5-1 plans, often used for tax planning or diversification rather than signaling negative outlook.